Tazokab

Tazokab

piperacillin + tazobactam

Manufacturer:

Fresenius Kabi

Distributor:

Fresenius Kabi
Concise Prescribing Info
Contents
Piperacillin Na, tazobactam Na
Indications/Uses
Adult & adolescent: Severe pneumonia including hospital-acquired & ventilator associated pneumonia; complicated UTI (including pyelonephritis); complicated intra-abdominal infections; complicated skin & soft tissue infections (including diabetic foot-infections). Patients w/ bacteraemia that occur in associated w/ or is suspected to be associated w/ any of the infections. Childn 2-12 yr: Complicated intra-abdominal infections. Management of neutropenic children w/ fever suspected to be due to a bacterial infection.
Dosage/Direction for Use
Adult & adolescent Infections 4 g piperacillin/0.5 g tazobactam every 8 hr. Nosocomial pneumonia & bacterial infections in neutropenic patient 4 g piperacillin/0.5 g tazobactam every 6 hr. Severe pneumonia & neutropenic adult w/ fever suspected to be due to a bacterial infection 4 g piperacillin/0.5 g tazobactam every 6 hr. Complicated UTI (including pyelonephritis) & intra-abdominal infections, skin & soft tissue infections (including diabetic foot infections) 4 g piperacillin/0.5 g tazobactam every 8 hr. Renal impairment CrCl 20-40 mL/min Max: 4 g piperacillin/0.5 g tazobactam every 8 hr, <20 mL/min Max: 4 g piperacillin/0.5 g tazobactam every 12 hr. Haemodialysis 1 additional dose of 2 g piperacillin/0.25 g tazobactam following each dialysis period. Childn 2-12 yr Neutropenic childn w/ fever suspected to be due to bacterial infections 80 mg piperacillin/10 mg tazobactam/kg every 6 hr. Max: 4 g piperacillin/0.5 g tazobactam/dose over 30 min. Complicated intra-abdominal infections 100 mg piperacillin/12.5 mg tazobactam/kg every 8 hr. Max: 4 g piperacillin/0.5 g tazobactam/dose over 30 min. Renal impairment ≤50 mL/min 70 mg piperacillin/8.75 mg tazobactam/kg every 8 hr. Haemodialysis 1 additional dose of 40 mg piperacillin/5 mg tazobactam/kg following each dialysis period.
Contraindications
Hypersensitivity to piperacillin Na, tazobactam Na or to any other penicillin-antibacterial agent. History of acute severe allergic reaction to any other β-lactam active substances (eg, cephalosporin, monobactam or carbapenem).
Special Precautions
Previous hypersensitivity reactions to penicillins, other β-lactam agents (eg, cephalosporin, monobactam or carbapenem) & other allergens. Discontinue if serious hypersensitivity reactions occur. Monitor closely if patient develops skin rash & discontinue if lesions progress. Discontinue if pseudomembranous colitis symptoms & bleeding manifestations occur. Emergence of resistant organisms which may cause superinfections. Leukopenia & neutropenia may occur especially during prolonged therapy. Convulsion may occur when high-dosed are administered especially in patients w/ impaired renal function. Patients on controlled Na diet. Hypokalaemia may occur in patients w/ low K reserves or those receiving drugs that lower K levels. Perform periodic assessment of haematopoietic function & electrolyte determination. False +ve w/ non-enzymatic methods for measuring urinary glucose; chemical urine protein measurements methods; Platelia Aspergillus EIA test. Cross-reactions w/ non-Aspergillus polysaccharides & polyfuranoses w/ Platelia Aspergillus EIA test. +ve direct Coombs' test. Renal impairment or in hemodialysis patients. Pregnancy & lactation. Childn <2 yr.
Adverse Reactions
Diarrhea. Candida infection; thrombocytopenia, anaemia; insomnia; headache; abdominal pain, vomiting, nausea, constipation, dyspepsia; rash, pruritus; pyrexia, inj site reaction; increased ALT, AST, blood creatinine, blood alkaline phosphatase & blood urea; decreased total protein & blood albumin, +ve direct Coombs' test; prolonged activated partial thromboplastin time.
Drug Interactions
Prolongation of the neuromuscular blockage of vecuronium. May reduce excretion of methotrexate. Longer t½ & lower renal clearance w/ probenecid. Inactivation of tobramycin & gentamicin in patients w/ severe renal impairment. Increased incidence of acute kidney injury w/ vancomycin. Simultaneous administration of heparin, oral anticoagulants & other substances that may affect the blood coagulation system including thrombocyte function.
MIMS Class
Penicillins
ATC Classification
J01CR05 - piperacillin and beta-lactamase inhibitor ; Belongs to the class of penicillin combinations, including beta-lactamase inhibitors. Used in the systemic treatment of infections.
Presentation/Packing
Form
Tazokab powd for soln for IV infusion 2 g/250 mg
Packing/Price
50 mL x 10 × 1's
Form
Tazokab powd for soln for IV infusion 4 g/500 mg
Packing/Price
50 mL x 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in